Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | opioid receptor, mu 1 | Starlite/ChEMBL | No references |
Homo sapiens | p21 protein (Cdc42/Rac)-activated kinase 4 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Brugia malayi | serine/threonine-protein kinase PAK 7 | Get druggable targets OG5_131977 | All targets in OG5_131977 |
Echinococcus multilocularis | serine:threonine protein kinase PAK 4 | Get druggable targets OG5_131977 | All targets in OG5_131977 |
Loa Loa (eye worm) | STE/STE20/PAKB protein kinase | Get druggable targets OG5_131977 | All targets in OG5_131977 |
Echinococcus granulosus | serine:threonine protein kinase PAK 4 | Get druggable targets OG5_131977 | All targets in OG5_131977 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | protein kinase, putative | 0.0019 | 0 | 0.5 |
Giardia lamblia | Kinase, STE STE20 | 0.0019 | 0 | 0.5 |
Trichomonas vaginalis | STE family protein kinase | 0.0019 | 0 | 0.5 |
Entamoeba histolytica | protein kinase, putative | 0.0019 | 0 | 0.5 |
Schistosoma mansoni | subfamily S1A unassigned peptidase (S01 family) | 0.0096 | 0.3813 | 1 |
Echinococcus multilocularis | serine:threonine protein kinase PAK 4 | 0.0202 | 0.9065 | 1 |
Entamoeba histolytica | protein kinase, putative | 0.0019 | 0 | 0.5 |
Trichomonas vaginalis | STE family protein kinase | 0.0019 | 0 | 0.5 |
Loa Loa (eye worm) | STE/STE20/PAKB protein kinase | 0.0221 | 1 | 1 |
Trichomonas vaginalis | STE family protein kinase | 0.0019 | 0 | 0.5 |
Onchocerca volvulus | 0.0096 | 0.3813 | 1 | |
Brugia malayi | Trypsin family protein | 0.0096 | 0.3813 | 0.3813 |
Entamoeba histolytica | p21-activated kinase | 0.0019 | 0 | 0.5 |
Entamoeba histolytica | protein kinase, putative | 0.0019 | 0 | 0.5 |
Echinococcus granulosus | serine:threonine protein kinase PAK 4 | 0.0202 | 0.9065 | 1 |
Schistosoma mansoni | subfamily S1A unassigned peptidase (S01 family) | 0.0096 | 0.3813 | 1 |
Trichomonas vaginalis | STE family protein kinase | 0.0019 | 0 | 0.5 |
Trichomonas vaginalis | STE family protein kinase | 0.0019 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (binding) | = 1745 nM | BindingDB_Patents: Enzymatic Assay. The enzymatic activity of PAK4 KD was measured by its ability to catalyzed the transfer of a phosphate residue from a nucleoside triphosphate to an amino acid side chain of a commercially available peptide (amino acid sequence EVPRRKSLVGTPYWM). | ChEMBL. | No reference |
EC50 (binding) | = 1745 nM | BindingDB_Patents: Enzymatic Assay. The enzymatic activity of PAK4 KD was measured by its ability to catalyzed the transfer of a phosphate residue from a nucleoside triphosphate to an amino acid side chain of a commercially available peptide (amino acid sequence EVPRRKSLVGTPYWM). | ChEMBL. | No reference |
Ki (binding) | = 58 nM | BindingDB_Patents: Binding Assay. Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement). | ChEMBL. | No reference |
Ki (binding) | = 67 nM | BindingDB_Patents: Enzymatic Assay. The enzymatic activity of PAK4 KD was measured by its ability to catalyzed the transfer of a phosphate residue from a nucleoside triphosphate to an amino acid side chain of a commercially available peptide (amino acid sequence EVPRRKSLVGTPYWM). | ChEMBL. | No reference |
Ki (binding) | = 67 nM | BindingDB_Patents: Enzymatic Assay. The enzymatic activity of PAK4 KD was measured by its ability to catalyzed the transfer of a phosphate residue from a nucleoside triphosphate to an amino acid side chain of a commercially available peptide (amino acid sequence EVPRRKSLVGTPYWM). | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.